Sponsor Dossier
Teva Pharma
Sponsor Dossier for Teva Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABIRATERONE-TEVA
- Brand: ACITRETIN-TEVA
- Brand: AJOVY
- Brand: APIXABAN-TEVA
- Brand: ARMODAFINIL-TEVA
- Brand: AUSTEDO
- Brand: AZACITIDINE-TEVA
- Brand: AZILECT
- Device (sponsor): Injector, medication/vaccine, syringe
About
Teva Pharma is an Australian Private Company with ABN 41169715664, registered in NSW. The entity is active and GST-registered from 2014.
Portfolio
Teva Pharma has 40 brands on the ARTG, of which 29 are indexable. Twenty-five brands have Product Information on file, nine brands have PBAC outcome records, and four brands have AusPARs on record.
Therapeutic focus
The portfolio is distributed across the following therapeutic areas: — Neurology: 21 brands — Oncology: 9 brands — Respiratory: 4 brands — Dermatology: 2 brands — Women's Health: 2 brands — Haematology: 2 brands
PBS footprint
Eight brands in Teva Pharma's portfolio have at least one PBS-listed item, with the latest PBS schedule date of 2026-05-01.
Regulatory activity
Teva Pharma's most recent PBAC outcome is dated 2024-03-01, with nine brands holding PBAC outcomes on record. The most recent AusPAR is dated 2023-01-17, with four brands holding AusPAR records.